Catalyst Biosciences Announces Plan to Distribute Cash to Stockholders
Board is Committed to Maximizing the Amount of Cash the Company Distributes to Stockholders Decision…
News
GBT Initiates Phase 2/3 Clinical Trial of GBT601 in Patients with Sickle Cell Disease
Phase 2 portion designed to identify the optimal dose for the pivotal Phase 3 portion…
Amolyt Pharma Strengthens Leadership Team with Appointment of Mark Sumeray, M.D., as Chief Medical Officer
Industry veteran brings over two decades of global experience in pharmaceutical, medical devices and biotech…
Humacyte Announces JAMA Surgery Publication Highlighting Potential of Human Acellular Vessel™ (HAV™) to Expand Vascular Trauma Reconstruction and Bypass Treatment Options
— HAV implanted in nearly 500 patients with more than 1,000 patient-years of follow up…
Advaxis Updates on the Phase 1 Clinical Trial of ADXS-504 for the Treatment of Early Prostate Cancer
Evaluation completed of first dose level in investigator-sponsored study in biochemically recurrent prostate cancer Enrollment…
Codiak Initiates Patient Dosing in Phase 1 Clinical Trial of exoASO™-STAT6 in Patients with Advanced Hepatocellular Carcinoma, Liver Metastases from Primary Gastric Cancer and Colorectal Cancer
exoASO-STAT6 is the third engineered exosome candidate generated from Codiak’s engEx® Platform to enter clinical…
Achieve Life Sciences Announces Initiation of Phase 2 ORCA-V1 Clinical Trial Evaluating Cytisinicline for Nicotine e-cigarette Cessation
SEATTLE and VANCOUVER, British Columbia, June 29, 2022 (GLOBE NEWSWIRE) — Achieve Life Sciences, Inc….
Galera Announces Results from Phase 1 Stage of GRECO-1 Trial of Rucosopasem with SBRT for NSCLC
Rucosopasem was safe and well tolerated Early indications of anti-cancer activity and pulmonary function preservation…
Mindset Pharma Announces Development of Novel, Optimized, Intranasal Formulation
Leverages Mindset’s Platform Technology for Efficient Delivery of CNS Therapeutics TORONTO, June 29, 2022 (GLOBE…
InflaRx Provides Development Update for Vilobelimab in Pyoderma Gangrenosum and Severe COVID-19
Orphan Drug Designation granted for treatment of pyoderma gangrenosum (PG) from US FDA and EMA…
VectivBio Announces Closing of $54 Million Aggregate Financing
BASEL, Switzerland, June 29, 2022 (GLOBE NEWSWIRE) — VectivBio Holding AG (“VectivBio”) (Nasdaq: VECT), a…
Neurona Therapeutics Announces Initial Subject Dosed in First Clinical Trial of Regenerative Human Cell Therapy, NRTX-1001, in Adults with Drug-Resistant Focal Epilepsy
Neurona has initiated dosing of a first-ever regenerative human cell therapy candidate in a Phase…
Surface Oncology Appoints Carsten Brunn to Board of Directors
CAMBRIDGE, Mass., June 29, 2022 (GLOBE NEWSWIRE) — Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company…
Tilray Medical Expands Portfolio of Medical Cannabis Products in the UK
LEAMINGTON, Ontario, June 29, 2022 (GLOBE NEWSWIRE) — Tilray Brands, Inc. (“Tilray” or the “Company”)…
Agenus Shows Unprecedented Activity for Botensilimab/Balstilimab Combination in Microsatellite Stable Colorectal Cancer at ESMO World GI Congress
Overall response rate of 24%, and disease control rate of 73%, in heavily pre-treated patients…
PharmaTher Announces Positive Results from Study For Ketamine Microneedle Patch
Successfully delivered ketamine and KETABET™ (ketamine and betaine) via microneedle patch, unlocking the potential for…
ALX Oncology Receives U.S. FDA Orphan Drug Designation for Evorpacept for the Treatment of Patients with Acute Myeloid Leukemia
SOUTH SAN FRANCISCO, Calif., June 29, 2022 (GLOBE NEWSWIRE) — ALX Oncology Holdings Inc., (“ALX…
AN2 Therapeutics Initiates Pivotal Phase 2/3 Trial Evaluating Epetraborole for Treatment-Refractory MAC Lung Disease
AN2 is developing epetraborole as a once-daily, orally administered treatment with a novel mechanism of…
McGuire Haulage Upgrades Vehicle Fleet With ORBCOMM’s Driver-Focused Truck Telematics Solution
Leverages integrated platform to view data and analytics through a single pane of glass, improving…
Progress Pushes the Limits of Multi-Cloud Monitoring and Threat Detection with Latest Release of Flowmon
Organizations can now achieve unified monitoring of their multi-cloud ecosystems from a single location while…